The problem 

End-stage liver disease is associated with a highly inflammatory and damaging systemic immune response that is unable to defend against bacterial and viral pathogens and is unable to maintain antitumoral immunity.

The approach 

To develop disease-specific host-targeted immunomodulatory strategies to rebalance this skewed equilibrium to restore a state of effective antipathogen and anticancer immunity and dampen injurious inflammatory processes.

Main discoveries and innovations

Identification of key therapeutic targets to restore immunological homeostasis in chronic liver disease.